May 1, 2015
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-4561
Attention: Matthew Jones
Re: | Biondvax Pharmaceuticals Ltd. |
Registration Statement on Form F-1
Filed April 30, 2015
File No. 333-201283
Dear Mr. Jones:
The undersigned, being the Registrant identified in Registration Statement No. 333-201283 requests to cancel its acceleration request submitted to the Securities and Exchange Commission on April 28, 2015.
Very truly yours, | |
/s/ Ron Babecoff | |
Ron Babecoff | |
Chief Executive Officer |